All In MedTech

FDA Clearance Tracker · P130029-S007

Fluency Plus Endovascular Stent Graft

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 5, 2017

Approved

Time to decision

178 days

Received Apr 10, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P130029-S007
Device name
Fluency Plus Endovascular Stent Graft
Applicant location
Tempe, AZ
Received
Apr 10, 2017
Decided
Oct 5, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P130029

Device type

Device class
Class III

Every decision under product code PFV

FDA's approval statement

As written in FDA's record.

Approval for an update to the labeling to include the 24-month data on patients enrolled in the clinical study.

Source documents

Other decisions for Bard Peripheral Vascular, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.